MX2019003907A - Combinaciones farmaceuticas de inhibidor de histona desacetilasa e inhibidor de proteasoma o farmaco inmunomodulador para el tratamiento de cancer hematologico. - Google Patents

Combinaciones farmaceuticas de inhibidor de histona desacetilasa e inhibidor de proteasoma o farmaco inmunomodulador para el tratamiento de cancer hematologico.

Info

Publication number
MX2019003907A
MX2019003907A MX2019003907A MX2019003907A MX2019003907A MX 2019003907 A MX2019003907 A MX 2019003907A MX 2019003907 A MX2019003907 A MX 2019003907A MX 2019003907 A MX2019003907 A MX 2019003907A MX 2019003907 A MX2019003907 A MX 2019003907A
Authority
MX
Mexico
Prior art keywords
inhibitor
immunomodulatory drug
hematological cancer
histone deacetylase
cancer
Prior art date
Application number
MX2019003907A
Other languages
English (en)
Inventor
Jin Kim Soo
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of MX2019003907A publication Critical patent/MX2019003907A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona a una combinación farmacéutica para tratar un cáncer hematológico que comprende el inhibidor de histona desacetilasa (HDAC) de la fórmula química 1, un inhibidor de proteasoma o un fármaco inmunomodulador y un agente anti-cáncer esteroidal conjuntamente. La combinación farmacéutica de la presente invención puede ser útil para tratar un cáncer hematológico tal como mieloma múltiple, al reducir la toxicidad que es el problema del inhibidor de HDAC convencional y que exhibe un nivel equivalente de efectos farmacéuticos debido al mecanismo inhibidor complejo contra el cáncer del compuesto de la fórmula química 1 y su sal farmacéuticamente aceptable, el inhibidor de proteasoma o el fármaco inmunomodulador y el agente anti-cáncer esteroidal.
MX2019003907A 2016-10-04 2017-09-29 Combinaciones farmaceuticas de inhibidor de histona desacetilasa e inhibidor de proteasoma o farmaco inmunomodulador para el tratamiento de cancer hematologico. MX2019003907A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160127767A KR102002581B1 (ko) 2016-10-04 2016-10-04 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
PCT/KR2017/011015 WO2018066946A1 (en) 2016-10-04 2017-09-29 Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer

Publications (1)

Publication Number Publication Date
MX2019003907A true MX2019003907A (es) 2019-08-05

Family

ID=61832016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003907A MX2019003907A (es) 2016-10-04 2017-09-29 Combinaciones farmaceuticas de inhibidor de histona desacetilasa e inhibidor de proteasoma o farmaco inmunomodulador para el tratamiento de cancer hematologico.

Country Status (11)

Country Link
EP (1) EP3522891A4 (es)
JP (2) JP2019529562A (es)
KR (1) KR102002581B1 (es)
CN (1) CN109789138A (es)
AU (1) AU2017338564B2 (es)
BR (1) BR112019006633A2 (es)
CA (1) CA3038019A1 (es)
MX (1) MX2019003907A (es)
RU (1) RU2721409C1 (es)
WO (1) WO2018066946A1 (es)
ZA (1) ZA201902340B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7415973B2 (ja) 2021-02-12 2024-01-17 信越化学工業株式会社 化学増幅ポジ型レジスト組成物及びレジストパターン形成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010750A1 (en) * 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2007054719A2 (en) * 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
CA2659070C (en) * 2006-09-15 2014-10-21 Janssen Pharmaceutica Nv Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
CA2750639A1 (en) * 2009-01-23 2010-07-29 Cancer Research Technology Limited Hedgehog pathway inhibitors
KR101168801B1 (ko) 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
US8610434B2 (en) 2011-07-21 2013-12-17 ColdEdge Technologies, Inc. Cryogen-free cooling system for electron paramagnetic resonance system
WO2013021032A1 (en) * 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
KR102414005B1 (ko) * 2012-08-09 2022-06-27 셀진 코포레이션 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
WO2015054175A1 (en) * 2013-10-11 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deactylase inhibitors and immunomodulatory drugs
TR201900057T4 (tr) * 2013-12-12 2019-01-21 Chong Kun Dang Pharmaceutical Corp Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler.

Also Published As

Publication number Publication date
EP3522891A1 (en) 2019-08-14
EP3522891A4 (en) 2020-04-15
ZA201902340B (en) 2020-08-26
JP2019529562A (ja) 2019-10-17
CN109789138A (zh) 2019-05-21
RU2721409C1 (ru) 2020-05-19
BR112019006633A2 (pt) 2019-07-02
AU2017338564B2 (en) 2020-07-09
CA3038019A1 (en) 2018-04-12
JP2021020953A (ja) 2021-02-18
KR102002581B1 (ko) 2019-07-22
KR20180037507A (ko) 2018-04-12
AU2017338564A1 (en) 2019-05-02
WO2018066946A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
MX2022012825A (es) Inhibidores de inmunoproteasoma.
MX2019008436A (es) Inhibidores del inmunoproteasoma.
MX2019012522A (es) Compuestos y metodos terapeuticos.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
MX2019003907A (es) Combinaciones farmaceuticas de inhibidor de histona desacetilasa e inhibidor de proteasoma o farmaco inmunomodulador para el tratamiento de cancer hematologico.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2020005036A (es) Inhibidores de inmunoproteasoma.
MY198083A (en) Bicyclic pyridine compound
PH12018501100A1 (en) Phenylimidazole compound
MX2019003374A (es) Composicion combinada para prevenir o tratar cancer que comprende un derivado de benzofenona tiazol como un vda e inhibidor de topoisomerasa.
EA201270311A1 (ru) Конденсированное гетероциклическое производное и его применение
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний